HAVCR1 and renal cell carcinoma: A post-hoc analysis from the ASSURE trial, which evaluated the benefit of adjuvant sunitinib or sorafenib vs. placebo in high-risk resected RCC patients, found a significant association between high levels of circulating KIM-1 post-nephrectomy and worse disease-free survival (DFS) (HR: 0.56, P < 0.001) and OS (HR: 0.71, P < 0.001) [90].